Swiss Luxury Stock News

Galenica (SWX:GALE) has reaffirmed its 2026 outlook, guiding for sales growth of 5% to 7% and EBIT growth of 6% to 8%, a key reference point for investors monitoring the stock. See our latest analysis for Galenica. Galenica's latest confirmation of its 2026 outlook comes after a period where the share price has fallen 14.58% year to date and 11.15% over three months, yet the 1 year total shareholder return of 0.58% and 5 year total shareholder return of 49.93% point to a steadier long term...

Novartis (SWX:NOVN) is back in focus after releasing late stage trial results for Cosentyx in polymyalgia rheumatica and Vanrafia in IgA nephropathy, with both programs showing statistically significant efficacy and supportive safety data. See our latest analysis for Novartis. These late stage results for Cosentyx, Vanrafia, Scemblix and Pluvicto arrive as Novartis trades at CHF117.98, with a 1 month share price return of 4.08% and a 1 year total shareholder return of 25.23%. This suggests...

Ypsomed Holding AG has announced an increased annual dividend of CHF 2.70 per share, paid on July 7, 2026, with an ex-date of July 3 and record date of July 6. This higher cash return to shareholders may reflect management’s confidence in the business while adding an income component to the investment case. We’ll now consider how this higher annual dividend influences Ypsomed’s broader investment narrative built around its B2B focus and capacity expansion. Invest in the nuclear renaissance...

Nestlé (SWX:NESN) is back in focus after announcing a collaboration with US based Helaina to explore bioactive proteins for infant formula, aiming to more closely mirror components found in human milk. See our latest analysis for Nestlé. The Helaina collaboration comes as momentum in Nestlé's share price has been subdued, with the stock at CHF76.96 and a 1 year total shareholder return that declined 7.6% while the 5 year total shareholder return is down 21.0%. This suggests that investors are...

In recent weeks, Partners Group Holding capped withdrawals on an US$8.6 billion evergreen private equity fund after investor redemption requests exceeded its 5% quarterly limit, joining other private-credit players in tightening liquidity to protect long-term investors. The move underscores how the rapid growth of semi-liquid private-market products can expose firms like Partners Group to shifts in individual investor sentiment and liquidity needs. Next, we’ll examine how Partners Group’s...

In recent weeks, Roche and its subsidiaries reported a series of developments, including FDA approval of FoundationOne CDx as a companion diagnostic for Genentech’s Itovebi regimen in PIK3CA‑mutated HR‑positive, HER2‑negative breast cancer, US FDA Priority Review acceptance for oral SERD giredestrant in early ER‑positive, HER2‑negative breast cancer, advancing Phase II/III obesity candidates enicepatide and petrelintide, and launching an AI‑enabled Liver Disease Panel in Europe alongside a...

Medartis Holding (SWX:MED) recently highlighted progress in its hand and wrist business, featuring the TOUCH prosthesis, and reaffirmed guidance for 16% to 18% organic growth along with a high teens EBITDA margin that management associates with ongoing operational expansion. See our latest analysis for Medartis Holding. Investors have seen some pressure on Medartis Holding's share price recently, with the 90 day share price return down 6.5% and the year to date share price return down 10.8%...

Burckhardt Compression Holding (SWX:BCHN) has drawn investor attention after reporting record operating income and a higher EBIT margin of 13.3%, while reaffirming its CHF 18.00 dividend and issuing 2026 sales and margin guidance. See our latest analysis for Burckhardt Compression Holding. The share price has been under pressure despite the earnings headlines, with the 30 day share price return down 11.57% and the 1 year total shareholder return down 24.03%. The 5 year total shareholder...

Medacta Group SA ( VTX:MOVE ), is not the largest company out there, but it saw significant share price movement during...

In recent days, Novartis reported Phase III data showing that Vanrafia slowed kidney function decline in IgA nephropathy and Cosentyx improved sustained remission and reduced steroid use in polymyalgia rheumatica, with results published and presented at major medical congresses. Together, these late-stage readouts highlight Novartis’s push to expand existing franchises into specialty kidney and rheumatology indications where treatment options are limited. Next, we’ll examine how Cosentyx’s...

Recent performance snapshot for PolyPeptide Group PolyPeptide Group (SWX:PPGN) has drawn attention after a mixed stretch for the stock, with the price down 3.4% on the day and about 9.2% over the past month, but up 53.3% over the past 3 months. At a last close of CHF 36.40 and a market value of roughly CHF 1.2b, the company operates in a specialist niche, supplying synthetic peptides as active ingredients and intermediates for a range of therapeutic products worldwide. See our latest analysis...

Kuehne + Nagel International (SWX:KNIN) is back in focus after an external research firm upgraded the stock to its highest rating, citing improved earnings prospects and a stronger underlying business outlook. See our latest analysis for Kuehne + Nagel International. The fresh upgrade comes after a period of improving momentum, with a 7-day share price return of 6.38% and a 90-day share price return of 10.96%, even though the 5-year total shareholder return is down 25.69%. If this shift in...

Recent share performance context ABB (SWX:ABBN) has been drawing attention after a period of strong multi year total returns and steady reported revenue and net income growth. This has prompted investors to reassess the stock’s recent move in relation to its fundamentals. See our latest analysis for ABB. The recent pullback, with a 1 day share price return of 1.84% and 7 day share price return of 0.62%, comes after a strong run, including a 90 day share price return of 25.11% and a 1 year...

Roche Holding (SWX:ROP) has received FDA Priority Review for giredestrant as an adjuvant therapy in ER-positive, HER2-negative early-stage breast cancer. The filing is supported by phase III lidERA data, which showed a significant improvement in disease-free survival compared with current standard-of-care endocrine therapy. The Priority Review focuses on use of giredestrant after surgery, where adjuvant options have seen limited change for more than two decades. Roche is a large global...

Why Partners Group’s redemption cap matters for shareholders Partners Group Holding (SWX:PGHN) has limited withdrawals from its $8.6b evergreen private equity fund to 5% of net asset value per quarter after redemption requests reached an estimated 9.8% in the second quarter. The stock has come under pressure, with shares down about 18% over the past month and roughly 31% year to date, as investors reassess liquidity risks and the business impact of tighter fund gates. See our latest analysis...

Tecan’s India move and what it means for the stock Tecan Group (SWX:TECN) has launched direct operations in India, setting up a local sales and service team in Gurugram and formalizing Tecan India as part of its broader regional expansion. This step follows the company’s move into South Korea in 2024 and gives Tecan closer access to pharmaceutical, biotechnology, academic and diagnostic customers in one of the fastest growing life sciences markets. See our latest analysis for Tecan Group. The...

As European markets navigate the complexities of geopolitical developments and economic adjustments, the pan-European STOXX Europe 600 Index shows modest gains, reflecting investor optimism amid global uncertainties. With this backdrop, dividend stocks in Europe present a compelling opportunity for investors seeking stable income streams; these stocks are often characterized by strong fundamentals and consistent payout histories that can provide resilience in fluctuating market conditions.

ABB (SWX:ABBN) has integrated its power systems as SimReady 3D digital assets into NVIDIA's Omniverse DSX Blueprint. The partnership focuses on virtual modeling, validation, and optimization of data center power distribution for AI workloads before facilities are built. The announcement extends ABB's digital twin and AI infrastructure offering for large scale, energy focused data centers. ABB comes into this announcement with the share price at CHF86.1 and very strong recent returns,...

As European markets show cautious optimism amid geopolitical developments and economic adjustments, investors are increasingly focused on identifying growth opportunities with strong fundamentals. In this context, companies with high insider ownership often attract attention as they may indicate a strong alignment of interests between management and shareholders, potentially offering resilience in uncertain market conditions.

Shareholders appeared to be happy with LEM Holding SA's ( VTX:LEHN ) solid earnings report last week. This reaction by...

Novartis (SWX:NOVN) reported long term clinical data for Scemblix showing sustained superior efficacy and a favorable safety profile in chronic myeloid leukemia. The company also released expanded clinical evidence for Pluvicto in prostate cancer, underscoring progress in its radioligand therapy franchise. These data come from pivotal clinical trials and mark important milestones for Novartis in hematology and oncology. For investors tracking large pharma, these updates touch two core...

Landis+Gyr Group (SWX:LAND) is back on investors’ radar after its 2026 Capital Markets Day in New York, where the company outlined new Connected Platforms and Grid Intelligence segments and reaffirmed mid term growth expectations through 2028. See our latest analysis for Landis+Gyr Group. The CHF52.0 share price has seen a 4.31% 1 day share price return around the Capital Markets Day update, while the 1 year total shareholder return of 3.27% contrasts with a decline over the 3 year period of...

Roche Holding (SWX:ROP) is back in focus after a string of late May and early June product updates in obesity treatments and oncology, including fresh U.S. regulatory decisions and new clinical data presentations. See our latest analysis for Roche Holding. Despite the flurry of obesity and oncology updates, momentum in the shares has eased, with the 90 day share price return down 13.68% and the year to date share price return down 4.85%, even as the 1 year total shareholder return stands at...

Recent performance snapshot Idorsia (SWX:IDIA) has attracted fresh attention after a strong rebound over the past year, with the stock up about 166% over that period and showing gains across the past month and past 3 months. For investors tracking shorter time frames, Idorsia shares are up about 6% over the past week and around 19% over the past month, while the past 3 months show a gain of roughly 8%. See our latest analysis for Idorsia. Putting it together, Idorsia’s recent 1-day share...